Previous 10 | Next 10 |
2024-03-06 17:20:32 ET More on Arcturus Therapeutics Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments Arcturus: H1 2024 Rare Disease Drug Data On Deck Arcturus gets EU orphan drug status for cystic fibrosis drug Canacco...
2024-02-29 01:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today ann...
2024-02-21 13:04:28 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare. Essentially, they are responsible for improving ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster PR Newswire Study conducted by Meiji Seika Pharma in Japan Short communication follows previou...
2024-02-02 11:25:32 ET Summary Arcturus Therapeutics is a biotechnology company specializing in rare and infectious diseases, with approved COVID and influenza vaccines in Japan and the EU. The company is developing game-changing therapies for Ornithine Transcarbamylase Deficiency...
2024-01-31 17:20:05 ET Summary Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 bill...
2024-01-27 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster PR Newswire Study conducted by Meiji Seika Pharma in Japan Dat...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
On Tuesday, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced that it will present Phase 1 results in healthy volunteers and new Pha...
U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Tuesday. Shares of NVIDIA Corporation (NASDAQ:NVDA) rose during Tu...
Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024 First four CF patients demonstrated an average improvement of 4% FEV1 after two administrations Arcturus Therapeutics Holdings Inc. (the “Company”, ...